BioXcel Therapeutics Inc.

BTAI | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.18

-$0.54 (-74.96%)

Aug 28, 2026, 4:00 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-74.96%

(1D)

Rating

Updated: Aug 27, 2026

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $5.6M

1D Range

0.16 0.22

52W Range

0.16 4.29

Valuation (TTM)

PE -0.04

PB -0.05

EV/EBITDA -1.83

Valuation (NTM)

Forward PE N/A

Forward PEG N/A

Price Target $12

Cash Flow

FCF Yield -908.8%

SBC Adj. FCF Yield -941.4%

SBC Impact -3.6%

Margins

Gross Margin 45.3%

Operating Margin -6014.4%

FCF Margin -6860.4%

Growth (CAGR)

Revenue 3Y | 5Y 19.6% | N/A

Dil EPS 3Y | 5Y 31.3% | 18.1%

FCF 3Y | 5Y 19.2% | 2.7%

Returns

ROA -246.1%

ROE 69.9%

ROIC 1144.6%

Financial Health

Net Debt

$91.61M

Current Ratio 0.21

Interest Coverage -2.59

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative ther...

Sector Healthcare

Industry Biotechnology

Employees 29

IPO Date Mar 7, 2018

Website www.bioxceltherapeutics.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Latest Earnings

Aug 13, 2026

EPS

-$0.49

Beat +3.92%

YoY: +80.00%

REV

$182K

Beat +7.53%

YoY: +51.67%

Next Earnings

Nov 11, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Hold

Price Target

$4.50

Upside

+2380.71%

Buy (1)

Hold (1)

Sell (0)

Analyst Details ➞